Liabilities Breakdown
24.1 M
Current Liabilities
13.2 M
Long-Term Liabilities
| Total Liabilities | 35.13 Million | |
| Current Liabilities | 24.11 Million | |
| Long-Term Liabilities | 13.2 Million |
How much will CTI BioPharma owe in October?
 | By Rifka Kats | Macroaxis Story |
The stock is undergoing an active upward rally. CTI BioPharma Revenue Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 133,800. The current year Average Assets is expected to grow to about 73.2 M, whereas Net Income Per Employee is forecasted to decline to (1.7 M). As many investors are getting excited about healthcare space, it is fair to go over CTI BioPharma Corp as an investment option.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
The company currently holds 8.8 M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest CTI BioPharma is not taking enough advantage from borrowing. CTI BioPharma Corp has a current ratio of 5.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. CTi Biopharma financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of CTi Biopharma, including all of CTi Biopharma's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of CTi Biopharma assets, the company is considered highly leveraged. Understanding the composition and structure of overall CTi Biopharma debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.
How important is CTi Biopharma's Liquidity
CTi Biopharma financial leverage refers to using borrowed capital as a funding source to finance CTi Biopharma Corp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. CTi Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to CTi Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of CTi Biopharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between CTi Biopharma's total debt and its cash.
Breaking down the case for CTi Biopharma
The current price rise of CTI BioPharma Corp could raise concerns from investors as the firm it trading at a share price of 2.15 on slow start in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 30 days investing horizon is currently 14.64. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the CTI BioPharma partners.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of CTi Biopharma Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.